Bryn Mawr Capital Management LLC Raises Stock Holdings in Abbott Laboratories (NYSE:ABT)

Bryn Mawr Capital Management LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 22.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 92,284 shares of the healthcare product maker’s stock after acquiring an additional 16,785 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Abbott Laboratories were worth $10,158,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ABT. Rise Advisors LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $37,000. Stonehage Fleming Financial Services Holdings Ltd bought a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $40,000. Cornerstone Planning Group LLC lifted its stake in shares of Abbott Laboratories by 79.4% in the 3rd quarter. Cornerstone Planning Group LLC now owns 454 shares of the healthcare product maker’s stock worth $44,000 after purchasing an additional 201 shares during the period. Legacy Financial Group LLC bought a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $46,000. Finally, Briaud Financial Planning Inc bought a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $48,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Abbott Laboratories news, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction on Monday, January 29th. The shares were sold at an average price of $112.50, for a total transaction of $4,781,250.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at $7,315,537.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 12,500 shares of Abbott Laboratories stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the transaction, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock valued at $6,451,298. 1.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ABT shares. Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Citigroup raised their target price on shares of Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Barclays decreased their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, April 22nd. Raymond James restated a “buy” rating and set a $124.00 target price on shares of Abbott Laboratories in a research note on Wednesday. Finally, Royal Bank of Canada decreased their target price on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $121.50.

Abbott Laboratories Trading Up 0.6 %

Shares of ABT opened at $107.51 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The company has a 50 day simple moving average of $113.64 and a two-hundred day simple moving average of $108.03. The firm has a market cap of $186.55 billion, a P/E ratio of 33.49, a price-to-earnings-growth ratio of 2.57 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The firm had revenue of $9.96 billion during the quarter, compared to analyst estimates of $9.88 billion. During the same period last year, the firm posted $1.03 earnings per share. Abbott Laboratories’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, equities analysts expect that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.05%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.